摘要:

In the original treatment of recent cases of pulmonary tuberculosis, the R AMP-+INH regimen has given definitely better therapeutic results than the standard INH+SM regimen. The R AMP+EMB regimen was also more effective than the standard regimen the activity of which was similar to the R AMP+SM regimen. No relapses were observed among the cases treated with regimens containing R AMP, even when the treatment periods did not exceed 8 months. In the retreatment of chronic forms, the R AMP+PAS regimen produced stable sputum conversion in 67% of the cases, while the R AMP+EMB regimen was more effective (stable sputum conversion in 91% of the case). The first long-term controls confirm the good stability of the results produced by both treatments. Tolerance appeared excellent even though the length of treatment ranged from 8 to 24 months. Clinical signs of liver impairment were only observed in 3 of the cases treated (1.3%), but it was not clear in all cases whether these signs were linked to administration of R AMP.

ISSN:0025-7931    

DOI:10.1159/000194962

出版商:S. Karger AG    

年代:1971

数据来源: Karger

摘要:

In 18 cases of chronic pulmonary tuberculosis, in which secondary resistance to Rifampicin had developed, chemotherapy was analysed in order to find out whether resistance to this drug had developed despite the fact, that chemotherapy had been applied correctly or whether there was evidence that resistance developing was due to indiquate treatment. As a correct antitubercular chemotherapy is considered a simultaneous application of three antitubercular agents to which the bacilli are still sensitive. Only in 2 of these 18 cases Rifampicin had been given in combination with two drugs to which the pathogens were still sensitive. In all other 16 cases RMP was either given on its own, or in combination with only one other drug, or with drugs to which the pathogens had already developed resistance (pseudocombination). It must be assumed, that in the majority of these cases the cause of resistance developing to RMP was due to the fact, that chemotherapy had been inadequate and that the development of resistance to RMP could have been avoided by combining this agent with two adequate partner drugs.

ISSN:0025-7931    

DOI:10.1159/000194963

出版商:S. Karger AG    

年代:1971

数据来源: Karger

摘要:

The authors relate their experience of iterative interruption of air flow with two types of interruptors: mechanical rotative type and electromechanical type. The results of the so called ‘dynamic air way resistance’ obtained with these two types of apparatus are similar, both in normal subjects and asthmatic patients. Interpretation of mouth pressure interruptive curves of such patients as that of patients with chronic bronchitis or even some normal subjects, is always difficult. Nevertheless, this method is sufficiently accurate and reproductible to allow a good clinical approach of bronchial effects of Aleudrin, Acethylcholin and Allergenic substan

ISSN:0025-7931    

DOI:10.1159/000192804

出版商:S. Karger AG    

年代:1971

数据来源: Karger

摘要:

A series of 63 patients (divided into 2 groups) with chronic polyresistant very extensive pulmonary tuberculosis often complicated by associated pathology were treated with Rifampicin (RMP) under supervision in a sanatorium. In group 1 (26 cases) RMP had to be used alone as the last therapeutic chance. At the end of the 1st and 2nd year the sputum was negative in 14 of 26 patients (55%) and in 10 of 20 patients (50%), respectively. Five patients died. In group 2 (37 cases, including 10 with associated pneumoconiosis) RMP could be and was combined with another drug; ethambutol (EMB) in most cases. The sputum was negative in 28 of 37 cases (75 %) after 6 months and in 14 of 22 cases (68 %) after 9 months. Only 1 patient died. As expected, the radiological results in both groups were poor because of extensive fibrosis accompanying oldstanding lesions and associated respiratory pathology including pneumoconiosis. Our findings contribute in an objective way to our notion as to what can be expected of RMP in the treatment of the type of case in question. It is stressed that better results could be obtained by the use of three-drug combinations consisting of RMP, EMB and another drug.

ISSN:0025-7931    

DOI:10.1159/000194964

出版商:S. Karger AG    

年代:1971

数据来源: Karger

摘要:

A patient is described who developed respiratory distress or a ‘stiff-lung syndrome’ following lymphangiography. There was no evidence of pre-existing lung disease. Excessive accumulation of the oily medium with liberation of fatty acids in the lung probably was the result of an early operative manipulation of the retroperitoneal lymphatic system. Follow-up lung function studies showed a persistent impairment of diffusing capacity. Pulmonary complications of lymphangiography are briefly revi

ISSN:0025-7931    

DOI:10.1159/000192805

出版商:S. Karger AG    

年代:1971

数据来源: Karger

摘要:

Thirty patients have been treated with Rifampicin, ethambutol and/or other drugs. All had long-standing advanced tuberculosis with organisms resistant to the standard and often to older ‘reserve’ drugs. Four discharged themselves during the first month of treatment. Of the remaining 26, 24 have persistently negative cultures for M. tuberculosis, in 14 patients for 1 to 20 months after the end of two years of treatment. Tolerance was excellent and toxicity virtually abs

ISSN:0025-7931    

DOI:10.1159/000194965

出版商:S. Karger AG    

年代:1971

数据来源: Karger

摘要:

In reporting the limited case-list the autor confirms the following points: (a) Rifampicin (RMP) gives excellent results in the treatment of initial conditions of pulmonary tuberculosis positive for Koch’s bacillus. Negativization of the gastric content was observed regularly within 30–40 days, (b) Its bactericidal action is very important in cases which have received previous polyvalent treatment over several years and show resistant Koch’s bacillus, as conversion of the sputum was obtained in 85%. (c) RMP is the ideal drug for preoperative treatment of chronic pulmonary tuberculosis cases which must undergo surgery. The rapidity and regularity of the action, as well as the good tolerance, make RMP a first line antituberculose

ISSN:0025-7931    

DOI:10.1159/000194966

出版商:S. Karger AG    

年代:1971

数据来源: Karger

ISSN:0025-7931    

DOI:10.1159/000192806

出版商:S. Karger AG    

年代:1971

数据来源: Karger

摘要:

For previously untreated uncomplicated pulmonary tuberculosis together with Freerksen we can offer a ‘new standard therapy’: 10 mg/kg body wt. Rifampicin in association with 5–8 mg/kg body wt. isoniazid and 20–25 mg/kg body wt. ethambutol. This ‘new standard therapy’ leads to elimination of tubercle bacilli from sputum in all previously untreated patients. In cases of insufficient inhibitory serum concentrations streptomycin can be administered additionally. This intensive initial chemotherapy shortens the duration of treatment, which always gas to be in conformity with the individual development of t

ISSN:0025-7931    

DOI:10.1159/000194967

出版商:S. Karger AG    

年代:1971

数据来源: Karger

摘要:

The paper reports on a trial with Rifampicin (RMP,) used for 3 ½ years to treat a total of 250 patients. 202 of these patients could be followed up for periods of up to 42 months after discharge from the hospital. The negative findings achieved during inpatient treatment persisted throughout the whole period of follow-up observation. The radiological regression was also maintained, with increasing scar formation. In one case, a cavity transformed into a cyst was invaded by an aspergilloma 18 months after the patient’s discharge from hospital. With regard to tolerance, the trial of RMP gave favourable results. Tests did not show that RMP caused any greater increase in transaminases and bilirubin than other tuberculostatic agents. Liver biopsies were also done and showed no evidence of obvious hepatic damage at the beginning or later on in the course of treatment. It is possible that during its elimination from the liver RMP is in competition with bilirubin. Because of these precautions are indicated if the drug is given to patients with previous hepatic impairment, and above all chronic alcoholics, so that they, too, may benefit from highly tuberculostatic activity of the drug. RMP cannot be said to have any particularly toxic effect on the liv

ISSN:0025-7931    

DOI:10.1159/000194968

出版商:S. Karger AG    

年代:1971

数据来源: Karger